Additional 3.7 Million COVID-19 Pills Ordered

Pfizer Inc. recently announced it had reached an agreement with the United States (U.S.) Government to purchase an additional 3.7 million treatment courses of its authorized COVID-19 oral treatment, PAXLOVID™.

These PAXLOVID pills are planned for delivery by early 2023. 

This purchase supplements the 20 million treatment courses previously contracted by and already delivered to the U.S. Government.

In a press release on December 13, 2022, Pfizer stated that PAXLOVID plays an essential role in helping combat COVID-19-related hospitalizations and death in high-risk patients.

The oral treatment is currently authorized for conditional or emergency use in approximately 70 countries across the globe, including the U.S.

PAXLOVID is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness.

In June of 2022, Pfizer submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID patients at high risk of progression to severe disease from COVID-19.

The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is in February 2023.

Other COVID-19 treatment news (oral and IV) is posted at CoronavirusToday.com.